My understanding is:
1. Only CELZ can use the stem-cells derived from bonemarrow for ED. - Hence, CELZ has cornered the market - just taking time. This is how they are monetizing their patent - by preventing everyone else from getting into this area.
2. CELZ also have the 'exclusivity' for the use of the tool kit for this type of procedure. So, though CELZ cannot have a patent on the tool-kit, the supplier cannot sell the tool kit to any other purchaser who intends to use it in a similar way. We have seen technical papers where Gen 2 method of retrieving the stem cells is significantly more effective that the old Gen 1 was, using a 'centrifuge'.
So, basically, CELZ has 'double blocked' competition from entering this market till the patent expires (the patent was recently extended by 2 years(?) - please correct me)
I imagine if/when the peer reviewed article is published, this should spread like wild fire where the growth is only inhibited by speed of training new docs and supply chain.
Hope this helps.
Eagerly waiting.......
Market Data 
Markets 
